If you currently have an active urinary tract infection, discuss it with your clinician before starting Farxiga. The medication can increase glucose in urine, potentially worsening the infection, so treatment of the infection should be completed first.
Many patients experience modest weight loss (typically 1-3 kg) because calories are lost through urinary glucose excretion. This effect is considered an added benefit but varies between individuals.
Yes, the osmotic diuresis can lead to a modest reduction in systolic and diastolic blood pressure, especially in people who are volume-sensitive. Your clinician may monitor blood pressure after initiating therapy.
Moderate alcohol consumption is permissible, but excessive intake can increase dehydration and the risk of low blood pressure. Combine alcohol with caution, especially if you are also on diuretics.
Farxiga is usually taken in the morning to align with daily routines and to avoid nocturnal urination that might disrupt sleep. However, follow the timing advised by your prescriber.
Promptly treat the infection with an appropriate antifungal medication as prescribed, and inform your healthcare provider. Good genital hygiene and keeping the area dry can help prevent recurrence.
All SGLT2 inhibitors share the same basic mechanism, but they differ in dosing schedules, approved indications, and specific clinical trial data. Choice of agent depends on individual health status, renal function, and clinician preference.
Yes, if eGFR is ≥ 60 mL/min/1.73 m², Farxiga can be initiated at 5 mg. For eGFR between 30-60, a reduced dose (5 mg) may be used, but regular renal monitoring is essential.
Carry the medication in its original packaging with a copy of the prescription. Keep it at room temperature and stay hydrated, especially on long flights where fluid loss can be higher.
In many regions of the UK, Farxiga is listed on the NHS Drug Tariff for approved indications, but coverage may depend on local formulary decisions and the specific condition being treated. Check with your GP or pharmacist for details.
Farxiga is a prescription medicine used to help manage blood-sugar levels in adults with type 2 diabetes. The active ingredient in Farxiga is dapagliflozin, a member of the sodium-glucose co-transporter-2 (SGLT2) inhibitor class. It is supplied as an oral pill in two strengths: 5 mg and 10 mg. In the United Kingdom Farxiga is authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) and is marketed by AstraZeneca. The medication is prescription-only (POM) and is typically prescribed when diet, exercise, and first-line oral agents such as metformin do not achieve target glucose control.
Dapagliflozin blocks the SGLT2 protein located in the proximal tubules of the kidney. Under normal circumstances, SGLT2 re-absorbs about 90 % of the glucose filtered by the kidneys. By inhibiting this transporter, Farxiga reduces glucose re-absorption, allowing excess glucose to be expelled in the urine. This “urinary glucose loss” lowers circulating blood-sugar levels without directly stimulating insulin secretion.
Key pharmacologic points:
Farxiga is approved by the European Medicines Agency (EMA) and the MHRA for the following indications in the UK:
These uses align with NICE guidance (NG28, NG185) that recommends SGLT2 inhibitors for patients with type 2 diabetes who need additional glucose lowering and have a high cardiovascular or renal risk profile.
Some clinicians consider dapagliflozin for conditions that are not formally approved in the UK:
Disclaimer: Off-label use must be overseen by a qualified healthcare professional, with careful risk assessment and monitoring.
Overall, dapagliflozin has a low potential for CYP-mediated interactions, but the above combinations require clinical awareness.
Regular monitoring helps maximise benefit while minimising risk:
This article provides educational information about Farxiga and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
